AI-based analysis of tumor pathology slides can predict immunotherapy outcomes in rare cancers, according to a recent MD Anderson study.
Key Details
- 1MD Anderson researchers applied AI to analyze pathology slides from rare cancer patients undergoing immunotherapy.
- 2The AI tool rapidly quantified immune cell infiltration and tumor content using routine pathology slides.
- 3Combined metrics (immune infiltration increase and tumor content decrease) strongly predicted positive immunotherapy response.
- 4Patients with favorable markers had a 64% lower risk of progression or death and nearly quadrupled median survival (42 vs. 10 months).
- 5Study funded by Merck, with AI analysis support from Lunit.
- 6Further validation in larger cohorts is necessary before clinical adoption.
Why It Matters
This study demonstrates AI's potential to extract actionable insights from standard pathology, enabling tailored immunotherapy decisions for rare cancer patients. If validated, such approaches could significantly improve outcomes using data already collected in clinical workflows.
Source
EurekAlert
Related News
•EurekAlert
New G-AUDIT Tool Detects Hidden Bias in Medical AI Training Data
Johns Hopkins and FDA researchers unveil G-AUDIT, a tool to identify hidden biases in medical AI datasets before model training.
•EurekAlert
AI-Driven Bone Marrow Mapping Tool Improves Blood Cancer Assessment
Weill Cornell Medicine develops an AI tool to score and track disease severity in blood cancer from bone marrow imaging.
•EurekAlert
AI-Assisted Imaging Advances Precision in Brain Tumor Therapy Delivery
An AI-guided method improves intra-arterial therapy by mapping all tumor-feeding arteries to enhance delivery accuracy in malignant brain tumor treatment.